<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html>
<head>
<title>Activity of linezolid against nosocomial strains of Staphylococcus aureus in Russia: results of multicenter study</title>
<meta name="description" content="A.V.Dekhnich, L.S.Stratchounski, I.V.Edelstain, A.D.Narezkina, The StEnt Study Group. Activity of linezolid against nosocomial strains of Staphylococcus aureus in Russia: results of multicenter study">
<meta name="keywords" content="Activity, linezolid, nosocomial strains, Staphylococcus aureus, multicenter study, Russia, Dekhnich, Stratchounski, Edelstain, Narezkina, The StEnt Study Group">
<script language="JavaScript1.2"> <!--//
function btn(ind,picture) {document.images[ind].src=picture;}
//--> </script>

<script language="JavaScript"> <!--// 
document.write('<link rel="StyleSheet" type="text/css" href="/en/inc/');
if (navigator.appName=="Netscape") {
	document.write("nn")
} else {
	document.write("ie")
}
document.write('.css">');
//-->
</script>
<noscript><link rel="StyleSheet" type="text/css" href="../../inc/ie.css"></noscript>

<style type="text/css">
P {margin-top:10px; margin-left:10px; text-align:justify;}
LI {margin-top:8px; margin-left:15px; text-align:justify;}
H4 {margin-left:10px;}
H5 {font-size:11pt}
H5.l {text-align:left;}
</style>
</head>

<body class="main">

<table width="750" cellpadding="0" border="0" cellspacing="5">
<tr>
  <th width="150" valign="top">

  <table border="0" cellpadding="5" cellspacing="0" width="100%">
    <tr><td>
<p class="m10"><b>Antimicrobial Resistance</b></p>
<hr size="1" style="color: #D0C0AC;">
<p class="m8"><a href="../index.shtml#rus">Antimicrobial Resistance in Russia</a></p>
<p class="m8"><a href="../index.shtml#pub">Publications</a></p>
<p class="m8"><a href="../links.shtml">References</a></p>

    </td></tr>
  </table>
  

  </th><td valign="top">
<!--navigation-->
<map name="TopBtnEn">
<area shape="circle" coords="15,15,15" href="javascript:history.go(-1)" alt="Previous page" title="Previous page">
<area shape="circle" coords="46,15,15" href="javascript:history.go(+1)" alt="Next page" title="Next page">
<area shape="circle" coords="77,15,15" href="../../index-1.htm" alt="Main page" title="Main page">
<area shape="circle" coords="108,15,15" href="mailto:website@antibiotic.ru" alt="E-Mail" title="E-Mail">
</map>
<table border="0" cellpadding="0" cellspacing="0" width="100%"> <!--1-->
<tr>
  <td bgcolor="#F8F3E6" background="/rus/images/buttons/topline.gif" style="background-color: #F8F3E6; background-image: url(../../../rus/images/buttons/topline.gif);" width="98%" height="32"><img src="../../../rus/images/inv.gif" width="1" height="32" border="0" alt=""></td>
  <td width="1%"><font size="1"><img src="../../../rus/images/buttons/topbtn.gif" width="126" height="32" border="0" alt="Navigation" usemap="#TopBtnEn"></font></td>
</tr>
</table>
<!--/navigation-->

<h2><a name="top"></a>4<sup>th</sup> European Congress of Chemotherapy and Infection</h2>
<h5><i>4â€“7 May, 2002, Paris, France</i></h5>
<h5><b>Poster # PM221</b></h5>

<h1>Activity of linezolid against nosocomial strains of <i>Staphylococcus aureus</i> in Russia: results of multicenter study</h1>

<h5><i>V.A.&nbsp;Kretchikov, A.V.&nbsp;Dekhnich, L.S.&nbsp;Stratchounski</i></h5>

<h5 style="font-size:10pt; text-align:left; margin-left:10px;"><i>Institute of Antimicrobial Chemotherapy, Smolensk State Medical Academy, Russia</i></h5>

<p style="text-align:right; font-size:8pt"><a target="_blank" href="../../pdfs/pm221.pdf">The PDF format poster (101 kb) <img src="../../images/pdf.gif" width="16" height="16" alt="" border="0"></a></p>

<hr size="1">
<ul>
  <li><a href="#1">Abstract</a></li>
  <li><a href="#2">Introduction</a></li>
  <li><a href="#3">Purpose</a></li>
  <li><a href="#4">Materials and methods</a></li>
  <li><a href="#5">Results</a></li>
  <li><a href="#6">Conclusions</a></li>
</ul>
<hr size="1">

<a name="1"></a><br>
<h2>ABSTRACT</h2>

<p><b>Purpose:</b> to determine the susceptibility of nosocomial strains of <i>Staphylococcus aureus</i> to linezolid in different regions of Russia.</p>

<p><b>Methods:</b> a total of 879 clinical strains of <i>S.aureus</i> isolated in 2000-2001 from patients hospitalized in 17 medical institutions in different parts of Russia - 4 in Central region (Moscow, Ryazan, Smolensk), 2 in North-Western region (St.-Petersburg), 3 in Southern region (Krasnodar, Stavropol), 2 in Volga region (N.&nbsp;Novgorod, Kazan), 3 in Ural region (Ekaterinburg, Ufa), 3 in Siberia (Krasnoyarsk, Novosibirsk, Tomsk), were included in the study. Antimicrobial susceptibility testing was performed by agar dilution method in accordance with the NCCLS recommendations.</p>

<p><b>Results:</b> all tested strains including 295 MRSA strains (33.6% of all strains) were found to be susceptible to linezolid with the MIC ranged from 0.5 to 4&nbsp;mg/L. Both MIC<sub>50</sub> and MIC<sub>90</sub> were 2&nbsp;mg/L.</p>

<p><b>Conclusions:</b> linezolid had excellent <i>in vitro</i> activity that was not affected by resistance to other classes of antimicrobials, so it has a potential as an option for the treatment of nosocomial infections caused by <i>S.aureus</i> including MRSA.</p>

<a name="2"></a><br>
<h2>INTRODUCTION</h2>

<p><i>Staphylococcus aureus</i> is one of the most important pathogens that cause infections in hospitalized patients through the world. The resistance of this microorganism in both community and hospital settings to multiple antimicrobials is becoming more and more common. Treatment of infections caused by methicillin-resistant strains of <i>S.aureus</i> (MRSA) is one of the main problems of antimicrobial therapy in term of resistance of this pathogen to all <font face="Symbol">b</font>-lactams and to many other classes of antimicrobials. Such resistance leads to increased mortality and to decrease in cost-effectiveness of treatment. Glycopeptide antibiotic vancomycin has been the drug of choice for the treatment of the serious staphylococcal infections for the decades with no resistance emerged until the late 90s when first case of infection caused by MRSA with reduced susceptibility to vancomycin has been described. The only available antimicrobial with proved high activity against multiresistant <i>S.aureus</i>, including strains with reduced susceptibility to glycopeptides is linezolid. But there are no currently available data concerning the susceptibility of <i>S.aureus</i> to linezolid in Russia.</p>

<a name="3"></a><br>
<h2>PURPOSE</h2>

<p>To determine the susceptibility of nosocomial strains of <i>Staphylococcus aureus</i> to linezolid in different regions of Russia.</p>

<a name="4"></a><br>
<h2>MATERIALS AND METHODS</h2>

<p>A total of 879 clinical strains of <i>S.aureus</i> isolated in 2000-2001 from patients hospitalized in 17 hospitals in different parts of Russia (<a href="#f1">Fig.&nbsp;1</a>) were included in the study. The strains were identified using cultural growth test on mannitol-salt agar and tube coagulase test. The susceptibility testing was performed by agar- dilution method using Mueller-Hinton agar (Becton Dickinson, USA) supplemented with linezolid (Pharmacia, USA). Plates were inoculated with bacterial suspension using the multipoint inoculator (Mast Diagnostics Ltd, UK) approximately 10<sup>4</sup> CFU per spot and incubated in ambient air at 35<sup>o</sup>C for 24 hours. Interpretation of results was performed in accordance with NCCLS recommendations (2002). <i>S.aureus</i> ATCC<sup>&reg;</sup>29213 strain was used for quality control.</p>

<a name="f1"></a><br>
<div align="center"><img src="images/pm221.gif" width="467" height="215" alt="Geographical distribution of centers, participating in the study" border="0"></div>
<p><b>Figure 1.</b> Geographical distribution of centers, participating in the study</p>

<a name="5"></a><br>
<h2>RESULTS</h2>

<p>All tested strains including 295 MRSA strains (33.6% of all strains) were found to be susceptible to linezolid with the MIC ranged from 0.5 to 4&nbsp;mg/L. Both MIC<sub>50</sub> and MIC<sub>90</sub> were 2&nbsp;mg/L in all participating centers and for both methicillin-susceptible and methicillin-resistant strains.</p>

<a name="6"></a><br>
<h2>CONCLUSIONS</h2>

<p>Linezolid has an excellent <i>in&nbsp;vitro</i> activity that is not affected by resistance to other classes of antimicrobials, so it has a potential as an option for the treatment of nosocomial infections caused by <i>S.aureus</i> including MRSA.</p>

<br>
<!-- begin footer -->
<table border="0" cellpadding="5" cellspacing="0" width="100%">
<tr>
  <td style="text-align: left; vertical-align: bottom;" align="left" valign="bottom"><div class="t8">&copy; 2000-2006 IAC SSMA &middot; E-mail: <a href="mailto:website@antibiotic.ru" title="Send e-mail">website&#64;antibiotic&#46;ru</a></div></td>
  <td colspan="2" valign="top" align="right"><font size="1"><!-- SpyLOG v2 f:0211 --><script language="javascript">
u="u607.38.spylog.com";d=document;nv=navigator;na=nv.appName;p=1;
bv=Math.round(parseFloat(nv.appVersion)*100);
n=(na.substring(0,2)=="Mi")?0:1;rn=Math.random();z="p="+p+"&rn="+rn;y="";
y+="<a href='http://"+u+"/cnt?f=3&p="+p+"&rn="+rn+"' target=_blank>";
y+="<img src='http://"+u+"/cnt?"+z+
"&r="+escape(d.referrer)+"&pg="+escape(window.location.href)+"' border=0  width=88 height=31  alt='SpyLOG'>";
y+="</a>"; d.write(y);if(!n) { d.write("<"+"!--"); }//--></script><noscript>
<a href="../../../index-15.htm?f=3&p=1" target="_blank">
<img src="../../../digits.png?p=1" alt='SpyLOG' border='0' width="88" height="31">
</a></noscript><script language="javascript1.2"><!--
if(!n) { d.write("--"+">"); }//--></script><!-- SpyLOG  --></font></td>
</tr>
</table>
<!-- end of footer -->

  </td></tr>
</table>
</body>
</html>
